FR2712603B1 - Virus recombinants, préparation et utilisation en thérapie génique. - Google Patents

Virus recombinants, préparation et utilisation en thérapie génique.

Info

Publication number
FR2712603B1
FR2712603B1 FR9313772A FR9313772A FR2712603B1 FR 2712603 B1 FR2712603 B1 FR 2712603B1 FR 9313772 A FR9313772 A FR 9313772A FR 9313772 A FR9313772 A FR 9313772A FR 2712603 B1 FR2712603 B1 FR 2712603B1
Authority
FR
France
Prior art keywords
preparation
gene therapy
recombinant viruses
viruses
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9313772A
Other languages
English (en)
Other versions
FR2712603A1 (fr
Inventor
Jean-Francois Dedieu
Roux Aude Le
Michel Perricaudet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Gustave Roussy (IGR) filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR9313772A priority Critical patent/FR2712603B1/fr
Priority to AU81472/94A priority patent/AU8147294A/en
Priority to PCT/FR1994/001285 priority patent/WO1995014102A1/fr
Priority to ZA949104A priority patent/ZA949104B/xx
Priority to IL11168194A priority patent/IL111681A0/xx
Publication of FR2712603A1 publication Critical patent/FR2712603A1/fr
Application granted granted Critical
Publication of FR2712603B1 publication Critical patent/FR2712603B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
FR9313772A 1993-11-18 1993-11-18 Virus recombinants, préparation et utilisation en thérapie génique. Expired - Fee Related FR2712603B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR9313772A FR2712603B1 (fr) 1993-11-18 1993-11-18 Virus recombinants, préparation et utilisation en thérapie génique.
AU81472/94A AU8147294A (en) 1993-11-18 1994-11-07 Recombinant viruses coding for thymidine kinase in gene therapy
PCT/FR1994/001285 WO1995014102A1 (fr) 1993-11-18 1994-11-07 Adenovirus recombinants codant pour la thymidine kinase lors de therapie genique
ZA949104A ZA949104B (en) 1993-11-18 1994-11-16 Recombinant viruses and their use in gene therapy
IL11168194A IL111681A0 (en) 1993-11-18 1994-11-17 Recombinant viruses and their use in gene therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9313772A FR2712603B1 (fr) 1993-11-18 1993-11-18 Virus recombinants, préparation et utilisation en thérapie génique.

Publications (2)

Publication Number Publication Date
FR2712603A1 FR2712603A1 (fr) 1995-05-24
FR2712603B1 true FR2712603B1 (fr) 1996-02-09

Family

ID=9452977

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9313772A Expired - Fee Related FR2712603B1 (fr) 1993-11-18 1993-11-18 Virus recombinants, préparation et utilisation en thérapie génique.

Country Status (5)

Country Link
AU (1) AU8147294A (fr)
FR (1) FR2712603B1 (fr)
IL (1) IL111681A0 (fr)
WO (1) WO1995014102A1 (fr)
ZA (1) ZA949104B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
EP0575518A1 (fr) 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Procedes et compositions d'inhibition selective de l'expression de genes
EP0758387B1 (fr) * 1994-05-02 2001-12-19 University of Washington Mutants de la thymidine kinase
AU711269B2 (en) 1994-08-16 1999-10-07 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
ATE374247T1 (de) 1997-10-14 2007-10-15 Darwin Molecular Corp Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
CN1263854C (zh) 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
WO1999036544A2 (fr) 1998-01-14 1999-07-22 Chiron S.P.A. Antigenes du $i(neisseria meningitidis)
AU2678999A (en) 1998-02-13 1999-08-30 Genetrace Systems, Inc. Use of ribozymes for functionating genes
EP1645631B1 (fr) 1998-05-01 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
CN1074459C (zh) * 1998-11-25 2001-11-07 马丁 重组腺病毒－胸苷激酶构建体及其获得方法和用途
WO2000066741A2 (fr) 1999-04-30 2000-11-09 Chiron S.P.A. Antigenes de neisseria conserves
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
MXPA02006962A (es) 2000-01-17 2002-12-13 Chiron Spa Vacuna de vesicula de membrana exterior que comprende proteinas de membrana exterior de neisseria meningitidis serogrupo b.
GB0008966D0 (en) 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
CA2881568C (fr) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Acides nucleiques et proteines derives des groupes de streptocoques a et b
CN1405312A (zh) * 2001-01-18 2003-03-26 中山卫健生物科技有限公司 一种能特异性杀灭eb病毒相关肿瘤的重组病毒及其构建方法
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP2335724A1 (fr) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation contre la Chlamydia trachomatis
AU2003275127A1 (en) 2002-09-19 2004-04-08 Merial Limited P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
EP2085467B1 (fr) 2002-10-29 2013-12-11 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Polypeptides de Lutzomyia Longipalpis et méthodes d'utilisation desdits polypeptides
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
KR101222281B1 (ko) 2004-03-29 2013-01-28 가르파마 컴퍼니 리미티드 신규 갈렉틴 9 개변체 단백질 및 그 용도
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase
RS51324B (sr) 2005-04-25 2010-12-31 Merial Ltd. Vakcine protiv nipah virusa
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP1951751B1 (fr) 2005-11-14 2017-11-01 Merial, Inc. Thérapie génique pour insuffisance rénale
EP2035035A2 (fr) 2006-06-09 2009-03-18 Novartis AG Compositions immunogenes pour streptococcus agalactiae
CN103768588A (zh) 2008-05-08 2014-05-07 梅里亚有限公司 使用白蛉唾液免疫原的利什曼原虫疫苗
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
CA2837375C (fr) 2011-06-01 2019-07-16 Merial Limited Administration sans aiguille de vaccins contre le vsrrp
PT2734230T (pt) 2011-07-20 2019-02-27 Roussy Inst Gustave Vacina recombinante contra o vírus da leucemia felina contendo um gene de envelope do vírus da leucemia felina otimizado
CA2966191A1 (fr) 2014-11-03 2016-05-12 Merial, Inc. Procedes d'utilisation de formulations de vaccin par micro-aiguilles pour eliciter une immunite de protection contre le virus de la rage chez les animaux

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
WO1992005262A1 (fr) * 1990-09-14 1992-04-02 The John Hopkins University Procedes et compositions pour la therapie et la potentialisation genetiques de l'immunite antitumorale
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.

Also Published As

Publication number Publication date
FR2712603A1 (fr) 1995-05-24
WO1995014102A1 (fr) 1995-05-26
ZA949104B (en) 1995-07-21
IL111681A0 (en) 1995-01-24
AU8147294A (en) 1995-06-06

Similar Documents

Publication Publication Date Title
FR2712603B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2716893B1 (fr) Virus recombinants, leur préparation et leur utilisation thérapeutique.
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2712602B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
DK0595436T3 (da) Porcint respirations- og reproduktionssygdomsvirus, vacciner og viralt dna
FR2707664B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
NO950939L (no) Defektive adenovirusvektorer og deres anvendelse i gene-terapien
FR2704234B1 (fr) Virus recombinants, preparation et utilisation en therapie genique.
DE10399032I1 (de) Rekombinante Viren.
DE3853088T2 (de) Rekombinantes Avipoxvirus.
DE3850019D1 (de) Rekombinantes Avipoxvirus.
AU2328397A (en) Recombinant live feline immunodeficiency virus and proviral dna vaccines
AU1927797A (en) Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
FR2702152B1 (fr) Virus recombinants et leur utilisation en thérapie génique.
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
OA09664A (en) Virus/herbicide-resistance genes, processes for the preparation thereof and the use thereof
FR2706469B1 (fr) Polyisobutènes polyfonctionnels, leur préparation, leur formulation et leur utilisation.
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
NO974179D0 (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
CA2278808A1 (fr) Procedes pour la culture de cellules et la multiplication de virus
FR2717496B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
EP0227604A3 (fr) Emploi d'oligopeptides dans le traitement d'infections virales
FR2717823B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2717497B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
NO902248D0 (no) Renininhiberende peptider, deres fremstilling og anvendelse i legemidler.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20060731